USPTO Patent Grants - Therapeutics (A61P)

Small molecule compounds for treating lung epithelial and vascular endothelial cell injury

USPTO granted patent US12594282B2 to Guangzhou Cellprotek Pharmaceutical Co., Ltd. on April 7, 2026. The patent covers the use of 5α-androst-3β,5,6β-triol and analogues for treating pulmonary diseases mediated by lung epithelial cell injury and/or vascular endothelial cell injury. The compounds inhibit PFKFB3 expression and reduce vascular endothelial and alveolar epithelial cell injury.

Benzalkonium Chloride for Treating COVID-19 and Conjunctivitis

USPTO granted patent US12594251B2 to Bausch + Lomb Ireland Limited on April 7, 2026, covering methods of treating COVID-19 (including ocular manifestations) and conjunctivitis using benzalkonium chloride, as well as methods for reducing COVID-19 transmission using the compound. The patent, with inventors Patrick McCormick and Kimberly Millard, contains 40 claims and is classified under CPC codes A61K 31/14, A61P 27/02, and A61P 31/14.

LILRB2 Antibodies and Uses Thereof - Cancer and Autoimmune Treatment

The USPTO granted patent US12596122B2 to The Board of Regents of the University of Texas System covering LILRB2 antibodies and their uses for detecting and treating cancer and autoimmune diseases. The patent names 11 inventors and includes 26 claims. The filing date was January 28, 2021, under application number 17759800.

Methods of treating psoriasis with secukinumab

The USPTO granted patent US12594332B2 to Novartis AG covering novel regimens for treating psoriasis using secukinumab, an IL-17 antibody antagonist. The patent includes 11 claims directed to therapeutic methods employing the antibody. The patent application was filed on December 16, 2024, with inventors including Achim Guettner, Matthias Machacek, Charis Papavassilis, and Oliver Sander.

IL-17 antagonist compositions for treating inflammatory arthritis

USPTO granted patent US12594333B2 to Novartis AG covering methods of treating inflammatory arthritis using IL-17 antagonists, specifically IL-17 binding molecules such as secukinumab antibodies. The patent contains 16 claims and covers therapeutic regimens for conditions including psoriatic arthritis.

Bexagliflozin extended-release tablet, SGLT2 inhibitor formulation

The USPTO granted patent US12594243B2 to TheracosBio, LLC for an extended-release tablet formulation of the SGLT2 inhibitor bexagliflozin. The patent covers formulations designed to achieve lower peak plasma concentrations (Cmax) compared to immediate-release forms while maintaining therapeutic drug levels over extended periods. The patent contains 7 claims and provides intellectual property protection for the drug delivery technology through 2040.

Hydroflumethiazide composition for treating TNF-α-related diseases

USPTO granted Patent US12594279B2 to SK Chemicals Co., Ltd. for a composition containing hydroflumethiazide as an active ingredient for preventing or treating TNF-α-related diseases. The patent covers formulations effective at inhibiting TNF-α expression, demonstrating superior efficacy compared to methotrexate and hydroxychloroquine for rheumatoid arthritis treatment. The patent includes 8 claims and covers CPC classifications related to pharmaceutical compositions.

Prevention of tolerance to stimulant ADHD medication

USPTO granted patent US12594250B2 to James Martin Swanson for methods of preventing accumulated tolerance to stimulant medication used in ADHD treatment. The patent discloses pharmaceutical compositions with controlled-release formulations combining immediate-release and sustained-release components to counteract acute tolerance. The patent contains 16 claims covering methods of treatment using ascending delivery profiles.

Rhamnolipid compositions with antibiotics, UNC Chapel Hill patent

The USPTO granted patent US12594289B2 to The University of North Carolina at Chapel Hill on April 7, 2026, covering compositions combining biosurfactants (rhamnolipids) with antibiotics to enhance antibacterial potency against infections. The patent includes 18 claims and names Brian Conlon, Sarah Conlon, and Lauren Radlinski as inventors.

BOL-148 substance abuse treatment method patent grant to Ceruvia Lifesciences

The USPTO granted patent US12594272B2 to Ceruvia Lifesciences LLC covering a method of treating substance abuse using 2-bromo-lysergic acid diethylamide (BOL-148). The patent contains 6 claims and was filed on March 25, 2021, with Carey Turnbull listed as the inventor.

Amidines and amidine analogs for bacterial infection treatment

The USPTO granted Patent US12595251B2 to Georgia State University Research Foundation, covering amidine compounds and methods for treating bacterial infections or potentiating antibiotics. The patent names Binghe Wang, David W. Boykin, Manjusha Roy Choudhary, Arvind Kumar, Bingchen Yu, and Mengyuan Zhu as inventors. The patent, with 10 claims, covers CPC classifications including C07D compounds and A61P 31/04 (anti-infectives).

Substituted pyrimidine radical quenchers, Arizona State University

Substituted pyrimidine radical quenchers, Arizona State University

Aminopyridine compound as aldehyde trapping agent

USPTO granted Patent US12595259B2 to Zhuhai United Laboratories Co., Ltd. for an aminopyridine compound functioning as an aldehyde trapping agent, including formula (I) and its pharmaceutically acceptable salts. The patent covers 18 claims and has applications in ophthalmic therapeutics.

Fluorine-containing compound and anti-cancer medical use thereof

The USPTO granted patent US12595275B2 to Ascentawits Pharmaceuticals, Ltd. on April 7, 2026, covering a fluorine-containing compound (Formula II/III) with anti-cancer medical applications. The patent claims novel structures incorporating trifluoromethyl groups and fluorine-substituted aryl or heteroaryl groups at specific positions, with 17 total claims.

Dosing regimes for treatment of synucleinopathies

USPTO granted patent US12595295B2 to Prothena Biosciences Limited covering antibody dosing regimes for treatment of synucleinopathies. The patent specifies intravenous antibody dosing of 3000-5000 mg or 1300-1700 mg every 3-5 weeks. This grant provides exclusive intellectual property rights for these therapeutic dosing protocols.

Anti-follicle stimulating hormone receptor antibodies and methods of treatment

USPTO granted Patent US12595293B2 to The Wistar Institute covering isolated antibodies and antigen-binding fragments that specifically bind to Follicle Stimulating Hormone Receptor (FSHR), along with methods for treating diseases by administering these antibodies. The patent includes 14 claims and covers compositions for cancer treatment applications.

BIG3-PHB2 Interaction-Inhibiting Peptide Therapeutic Agent for Breast Cancer

USPTO granted patent US12595289B2 to Tokushima University for a therapeutic peptide that inhibits BIG3-PHB2 protein interaction, designed specifically for treating estrogen receptor-positive breast cancer. The peptide selectively targets BIG3-overexpressing cancer cells while avoiding expression of side effects. The patent covers 6 claims including the peptide composition and pharmaceutical formulation.

T cell receptors for mesothelin cancer immunotherapy

The USPTO granted patent US12595290B2 to Fred Hutchinson Cancer Center covering binding proteins (T cell receptors) specific for mesothelin peptides Msln20-28 and Msln530-538, along with compositions and recombinant host cells for cancer immunotherapy. The patent protects methods for treating mesothelioma, pancreatic cancer, ovarian cancer, and lung cancer using these binding proteins.

6-Thio-dG Treatment for Pediatric Brain Tumors

The USPTO granted Patent US12594293B2 to The Board of Regents of The University of Texas System on April 7, 2026, covering the use of 6-thio-dG (a telomerase substrate precursor analog) to treat therapy-resistant telomerase-positive pediatric brain tumors including diffuse intrinsic pontine glioma (DIPG), high-grade glioma (HGG), and high-risk medulloblastoma. Inventors Jerry Shay and Rachid Drissi developed methods demonstrating that 6-thio-dG induces telomere dysfunction-induced foci, genomic DNA damage, cell death, and tumor growth delay in xenograft models.

Probiotics to prevent cognitive dysfunction

USPTO granted patent US12593863B2 to INTERNATIONAL N&H DENMARK APS covering the use of Lacticaseibacillus paracasei bacteria for preventing or treating cognitive impairments, including those induced by sleep deprivation. The patent names Sile Griffin, Elaine Patterson, and Markus Lehtinen as inventors and includes 5 claims.

Cisplatin-Eugenol Analogue for Cancer Treatment

The USPTO granted Patent US12594338B2 to King Faisal Specialist Hospital & Research Centre for a cisplatin-eugenol compound with anti-cancer properties. The patent covers the compound composition, synthesis method, pharmaceutical formulations, and methods of cancer treatment. Inventors include Abdelilah Aboussekhra, Ibrahim Al-Jammaz, Basem Al-Otaibi, and Noura N. Alraouji. The patent was filed on July 27, 2023.

Nanoparticulate drug delivery for therapeutic applications

The USPTO granted Patent US12594347B2 to Duke University for compositions comprising self-assembling conjugates designed for nanoparticulate drug delivery. The patent covers conjugates with albumin binding domains and molecules having log D ≥ 1.5 at pH 7.4, intended for therapeutic applications including cancer treatment (A61P 35/00). Assignee: Duke University; Inventors: Parisa Yousefpour, Ashutosh Chilkoti.

Exosome Production Method for Cancer Therapeutic Delivery

USPTO granted patent US12594344B2 to China Medical University for a large-scale exosome production method using cyclic tensile bioreactors. The patent covers exosomes with anti-HLA-G protein configured as delivery vehicles for cancer therapeutic agents. The grant includes 10 claims and applies to A61P 35/00 (antineoplastic agents) and related CPC classifications.

Topiramate oral liquid suspension patent granted

USPTO granted patent US12594241B2 to inventors Paul Sudhakar and Scott Boyer for an oral liquid suspension formulation containing topiramate (Application No. 18462651). The patent contains 29 claims covering the composition and methods of medical treatment using the formulation. Generic and branded pharmaceutical manufacturers should assess this patent for potential freedom-to-operate implications.

HIV Oral Drug Composition Patent

The USPTO granted Patent US12594244B2 to Gilead Sciences, Inc. covering a solid oral dosage form combining tenofovir alafenamide, emtricitabine, and a compound of Formula I for HIV treatment. The patent contains 29 claims and was granted on April 7, 2026, with a filing date of September 29, 2025.

Vanda patents trichostatin A cancer treatment method

USPTO granted patent US12590162B2 to Vanda Pharmaceuticals Inc. covering a method of treating cancer using trichostatin A (TSA). Inventors include Mihael H. Polymeropoulos, Louis William Licamele, and Christian Lavedan. The patent contains 5 claims.

siRNA Septicemia Treatment Patent

USPTO granted Patent US12590304B2 to Suzhou Ribo Life Science Co., Ltd. covering an siRNA therapeutic targeting the kininogen (KNG) gene for treating septicemia. The patent includes 8 claims for the nucleic acid composition, pharmaceutical formulation, and siRNA conjugate. This is a standard patent grant公告 with no regulatory compliance obligations.

Fusion antibody for presenting antigen-derived T cell epitope

USPTO granted Patent US12590156B2 to AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION for a fusion antibody composition designed to deliver viral antigen-derived CD8+ T cell antigen epitopes to target cell cytoplasm for presentation on major histocompatibility complex class I (MHC-I) molecules. The patent contains 22 claims covering the composition and its use in antigen presentation.

Polymorph of EP4 receptor antagonist, preparation method and use

USPTO granted patent US12590103B2 to Shanghai Yuyao Biotech Ltd. for a stable polymorph of an EP4 receptor antagonist. The patent covers the solid-state form with improved stability over the amorphous compound, with claims directed to oncology, immunology, and bone disease applications.

GLP-1/GIP Dual Agonist Patent for Diabetes Treatment

USPTO granted patent US12589158B2 to Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. for long-acting GLP-1/GIP dual agonist compounds for treating Type II diabetes mellitus. The patent covers compounds with dual agonistic effects on glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors.

Benzimidazole and Benzimidazolone Based PROTAC Compounds for LRRK2 Degradation

The USPTO granted Arvinas Operations, Inc. patent US12589156B2 covering benzimidazole and benzimidazolone PROTAC compounds designed to recruit LRRK2 protein to E3 ubiquitin ligase for targeted degradation. The patent contains 12 claims and was filed on March 24, 2025.

Use of D9-methadone for postoperative pain relief

USPTO granted Patent US12590054B2 to the Board of Regents, The University of Texas System, covering the use of d9-methadone as an alternative formulation for methadone with improved pharmacokinetic properties for postoperative pain relief. The patent includes 15 claims and covers compositions and methods for managing pain following injury, disease, or surgery.

Crystalline acetylcholinesterase inhibitor forms A, B, C for neurodegenerative diseases

USPTO granted Patent US12590061B2 to Shanghai Institute of Materia Medica, Chinese Academy of Sciences covering crystalline forms A, B, and C of an acetylcholinesterase inhibitor compound (2-((1-(2-fluorobenzyl)-4-fluoropiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-1-indanone). The patent, filed November 24, 2020 as Application No. 17780449 with 10 claims, protects the stable, low-hygroscopicity crystalline forms used for preventing and treating neurodegenerative diseases.

Gilead PD-1/PD-L1 inhibitors, cancer treatment compounds

USPTO granted Gilead Sciences, Inc. Patent US12590062B2 for PD-1/PD-L1 inhibitor compounds for cancer treatment. The patent covers compounds according to formula (I), methods of using said compounds singly or in combination with additional agents, and compositions for treating cancer. Application No. 17098171 was filed November 13, 2020, and the patent contains 18 claims.

Antigen-presenting neutrophil-derived dendritic cells and methods of use thereof

The USPTO granted Patent US12589140B2 to The Brigham and Women's Hospital, Inc. covering methods for generating immune responses to cancer or infection by promoting differentiation of neutrophils into dendritic cells using GMCSF combined with immune complexes or anti-FcγRIIIB antibodies. The patent contains 14 claims and lists Tanya Mayadas, Vijaya Mysore, Xavier Cullere, and Jon C. Aster as inventors.

DNA Vaccine for Treating and Preventing Type 1 Diabetes

USPTO granted Patent US12589141B2 to The Fifth Medical Center of Chinese PLA General Hospital for a DNA vaccine using a B7-2-PE40 exotoxin fusion gene to treat Type 1 Diabetes. The patent, with 10 claims, covers reduction of blood glucose, restoration of insulin secretion, and reduction of islet cell autoantibody (ICA) and glutamate decarboxylase autoantibody (GAD) levels. The application was filed on March 2, 2020.

Viral vectors with RDH12 coding regions for treating retinal dystrophies

The USPTO granted Patent US12589136B2 to The Regents of the University of Michigan covering viral vectors comprising RDH12 coding regions and methods of using such vectors to treat retinal dystrophies, including Leber Congenital Amaurosis. The patent, with 12 claims, names Debra A. Thompson, Robin R. Ali, and Alexander J. Smith as inventors. The patent covers nucleic acids encoding human RDH12 protein and their use in gene therapy applications for ophthalmological conditions caused by loss-of-function mutations.

Aloe vera polysaccharide antimicrobial composition patent grant

USPTO granted Patent US12589130B2 to 2QR RESEARCH B.V. on March 31, 2026. The patent covers Aloe vera polysaccharide compositions with antimicrobial aggregating activity, having molecular weight of 30-100 kDa and comprising 80-100% w/w mannose. Inventors are Floris Koumans and Paul Kwakman. The patent has 14 claims.

Bacteriophages for treatment of tuberculosis

USPTO granted Patent US12589127B2 to the University of Pittsburgh for pharmaceutical compositions comprising five or more bacteriophages designed to treat Mycobacterium tuberculosis infections. The patent covers methods of treating drug-resistant TB and preventing activation of latent TB disease, with 20 claims covering the phage combinations and treatment methods.

Anaerostipes caccae Compositions for Treating Allergic and Autoimmune Diseases

USPTO granted Patent US12589122B2 to the University of Chicago on March 31, 2026, covering compositions and methods for treating infectious, autoimmune, allergic diseases, and food allergies using the bacterium Anaerostipes caccae. The patent includes methods for reducing allergic responses and preventing anaphylactic responses, with claims extending to compositions comprising the bacterium with prebiotics.

Treatment of cachexia using fibroblast cells and products thereof

USPTO granted patent US12589119B2 to Fibrobiologics, Inc. covering methods and compositions for treating cachexia using immune-modulating fibroblasts. Inventors Pete O'Heeron and Thomas Ichim disclosed compositions including immune-modulating fibroblasts for treatment, amelioration, or prevention of cachexia or inflammation related to cachexia. The patent contains 12 claims.

Phenylethynyl-thiophene compounds for treating degenerative disorders

The USPTO granted patent US12589090B2 to Aquilus Pharmaceuticals, Inc. covering phenylethynyl-thiophene compounds that inhibit caspase 3 for treating degenerative disorders including ALS, Huntington's disease, epilepsy, multiple sclerosis, Parkinson's disease, and Alzheimer's disease. The patent claims 2 compounds and methods for their use.

Elafibranor treats Primary Biliary Cholangitis, Genfit patent

Elafibranor treats Primary Biliary Cholangitis, Genfit patent

Ruxolitinib formulation for reduction of itch in atopic dermatitis

USPTO granted Patent US12589096B2 to Incyte Corporation on March 31, 2026. The patent covers a topical 0.75% or 1.5% ruxolitinib cream formulation administered two times per day for reducing itch in patients with atopic dermatitis. The patent includes 20 claims and names Michael Kuligowski, Kang Sun, Michael Howell, May Grace E. Venturanza, and Jim Lee as inventors.

Glucocorticoid receptor modulator relacorilant with paclitaxel patent granted

USPTO granted patent US12589094B2 to Corcept Therapeutics Incorporated on March 31, 2026, covering methods of co-administering glucocorticoid receptor modulator relacorilant with paclitaxel by reducing paclitaxel dose to approximately half when used together. The patent addresses drug-drug interaction management, noting that despite in vitro predictions of 5-fold increased paclitaxel exposure, in vivo co-administration showed only 80% increase, enabling a safer combination therapy for treating cancers such as ovarian and pancreatic.

C2-C7 alkyl boronic acids as antimicrobial antiviral therapeutic compounds

USPTO granted patent US12589103B2 to Cornell University covering methods for treating bacteria and viruses using C2-C7 alkyl boronic acids to reduce growth and virulence. The patent, filed October 7, 2020, names inventors Kenneth W. Simpson, Shiying Zhang, and Michael Fischbach and contains 28 claims.

Injectable sustained-release formulations for treatment of joint pain and inflammation

USPTO granted patent US12589102B2 to FORDOZ Pharma Corp. covering injectable drug-loaded microspheres combining steroidal and non-steroidal anti-inflammatory drugs for sustained release. The patent also protects methods of making the microspheres and using them to treat rheumatoid arthritis and osteoarthritis. The patent contains 9 claims and names inventors Sydney Ugwu, James He, and Zengli Fu.

ALPHA-1062 Pharmaceutical Composition for Treating Traumatic Brain Injury

USPTO granted Patent US12589099B2 to Alpha Cognition Inc. for a pharmaceutical composition containing ALPHA-1062 (or salt thereof) for treating confirmed or suspected traumatic brain injury (TBI). The patent includes 27 claims covering transmucosal/intranasal administration methods and a multi-use dispenser configuration. The composition may be self-preserving and anti-microbial.

Regeneron cyclodextrin protein drug conjugates

USPTO granted patent US12589101B2 to Regeneron Pharmaceuticals for cyclodextrin protein drug conjugates used in treating proliferative diseases. The patent contains 41 claims and covers compounds, compositions, and conjugates with cyclodextrin-based linker-payloads. Inventors: Amy Han and William Olson. Filing date: June 10, 2022.

Plasma kallikrein inhibitor patent for ocular disorders

The USPTO granted BioCryst Pharmaceuticals patent US12589093B2 covering plasma kallikrein inhibitor compositions for treating ocular disorders. The patent claims avoralstat-based drug compositions delivered via suprachoroidal space injection. The patent contains 16 claims and names inventors Yarlagadda Babu, Viral Kansara, and Rick McElheny.